Linda Higgins
Director/Board Member chez GALAPAGOS NV
Profil
Linda Slanec Higgins is currently a Non-Independent Non-Executive Director at Galapagos NV, a Director at Tizona Therapeutics, Inc., a Director at Arcus Biosciences, Inc., and a Senior VP-Research & External Innovation at Gilead Sciences, Inc. She previously worked as the Head-Research at Scios, Inc. and as the President, Chief Executive & Operating Officer at InteKrin Therapeutics, Inc. Dr. Higgins completed her undergraduate degree at Kenyon College and holds a doctorate from the University of California San Diego.
Postes actifs de Linda Higgins
| Sociétés | Poste | Début |
|---|---|---|
| GALAPAGOS NV | Director/Board Member | 22/10/2019 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2010 |
| ARCUS BIOSCIENCES, INC. | Director/Board Member | 10/08/2021 |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Director/Board Member | - |
Anciens postes connus de Linda Higgins
| Sociétés | Poste | Fin |
|---|---|---|
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Chief Tech/Sci/R&D Officer | - |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | President | 29/12/2010 |
Formation de Linda Higgins
| Kenyon College | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| GALAPAGOS NV | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Health Technology |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
